These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
480 related articles for article (PubMed ID: 31426130)
1. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer. Fan K; Fan Z; Cheng H; Huang Q; Yang C; Jin K; Luo G; Yu X; Liu C Cancer Med; 2019 Oct; 8(13):5903-5915. PubMed ID: 31426130 [TBL] [Abstract][Full Text] [Related]
2. Knockdown of Wang X; Su W; Qin C; Gao R; Shao S; Xu X; Zhang Z; Gao J Front Biosci (Landmark Ed); 2024 Jul; 29(7):269. PubMed ID: 39082329 [TBL] [Abstract][Full Text] [Related]
3. Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling. Cui J; Guo Y; Wu H; Xiong J; Peng T Mol Med; 2021 Apr; 27(1):38. PubMed ID: 33849427 [TBL] [Abstract][Full Text] [Related]
4. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway. Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522 [TBL] [Abstract][Full Text] [Related]
5. Resistance to gemcitabine is mediated by the circ_0036627/miR-145/S100A16 axis in pancreatic cancer. Yu S; Wang M; Zhang H; Guo X; Qin R J Cell Mol Med; 2024 Jun; 28(12):e18444. PubMed ID: 38924205 [TBL] [Abstract][Full Text] [Related]
6. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells. Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465 [TBL] [Abstract][Full Text] [Related]
7. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008 [TBL] [Abstract][Full Text] [Related]
8. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer. Kawaguchi K; Miyake K; Han Q; Li S; Tan Y; Igarashi K; Lwin TM; Higuchi T; Kiyuna T; Miyake M; Oshiro H; Bouvet M; Unno M; Hoffman RM Cell Cycle; 2018; 17(7):868-873. PubMed ID: 29623758 [TBL] [Abstract][Full Text] [Related]
9. SMYD2 Imparts Gemcitabine Resistance to Pancreatic Adenocarcinoma Cells by Upregulating EVI2A. Jin L; Qian D; Tang X; Huang Y; Zou J; Wu Z Mol Biotechnol; 2024 Oct; 66(10):2920-2933. PubMed ID: 37812330 [TBL] [Abstract][Full Text] [Related]
10. S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway. Liu Y; Bi T; Liu L; Gao Q; Shen G; Qin L Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):615-622. PubMed ID: 30683944 [TBL] [Abstract][Full Text] [Related]
11. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer. Fang Y; Zhou W; Rong Y; Kuang T; Xu X; Wu W; Wang D; Lou W Exp Cell Res; 2019 Oct; 383(1):111543. PubMed ID: 31374207 [TBL] [Abstract][Full Text] [Related]
12. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352 [TBL] [Abstract][Full Text] [Related]
13. Gemcitabine induces apoptosis and autophagy via the AMPK/mTOR signaling pathway in pancreatic cancer cells. Zhu J; Chen Y; Ji Y; Yu Y; Jin Y; Zhang X; Zhou J Biotechnol Appl Biochem; 2018 Sep; 65(5):665-671. PubMed ID: 29575133 [TBL] [Abstract][Full Text] [Related]
14. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists. Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473 [TBL] [Abstract][Full Text] [Related]
15. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210. Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003 [TBL] [Abstract][Full Text] [Related]
16. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts. Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568 [TBL] [Abstract][Full Text] [Related]
17. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer. Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599 [TBL] [Abstract][Full Text] [Related]
18. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC. Huang W; Hu X; He X; Pan D; Huang Z; Gu Z; Huang G; Wang P; Cui C; Fan Y Drug Resist Updat; 2024 May; 74():101079. PubMed ID: 38518727 [TBL] [Abstract][Full Text] [Related]
19. SUMO3 inhibition by butyric acid suppresses cell viability and glycolysis and promotes gemcitabine antitumor activity in pancreatic cancer. Zhu L; Chen G; Huang C; Gao H; Wang Y; Shen Y Biol Direct; 2024 Aug; 19(1):74. PubMed ID: 39183358 [TBL] [Abstract][Full Text] [Related]